X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (404) 404
humans (352) 352
glp-1 (338) 338
glp‐1 (334) 334
endocrinology & metabolism (332) 332
type 2 diabetes (289) 289
male (268) 268
diabetes (243) 243
diabetes mellitus, type 2 - drug therapy (241) 241
glucagon (221) 221
female (214) 214
glucagon-like peptide-1 (205) 205
insulin (189) 189
glucose (184) 184
middle aged (158) 158
animals (153) 153
diabetes mellitus (144) 144
hypoglycemic agents - therapeutic use (140) 140
liraglutide (140) 140
diabetes mellitus, type 2 - blood (122) 122
blood glucose - metabolism (115) 115
adult (113) 113
dextrose (107) 107
peptides (107) 107
exenatide (102) 102
glp‐1 analogue (101) 101
hypoglycemic agents (101) 101
diabetes therapy (100) 100
glp-1 analogue (100) 100
glycemic control (100) 100
glycosylated hemoglobin (99) 99
analysis (98) 98
hypoglycemic agents - administration & dosage (96) 96
aged (94) 94
metformin (92) 92
clinical trials (90) 90
diabetes mellitus, type 2 - metabolism (87) 87
obesity (87) 87
blood glucose - drug effects (82) 82
treatment outcome (82) 82
safety (75) 75
body weight (74) 74
double-blind (74) 74
double-blind method (74) 74
glucagon-like peptide 1 - analogs & derivatives (73) 73
original (73) 73
hypoglycemic agents - adverse effects (72) 72
glycated hemoglobin a - metabolism (69) 69
secretion (68) 68
glucagon-like peptide 1 (67) 67
open-label (66) 66
care and treatment (65) 65
mice (65) 65
original articles (65) 65
pharmacology & pharmacy (62) 62
rats (62) 62
beta-cell function (60) 60
hypoglycemia (59) 59
hypoglycemic agents - pharmacology (59) 59
type-2 diabetes-mellitus (59) 59
efficacy (58) 58
glucagon-like peptide-1 receptor (58) 58
glucagon-like peptide-1 receptor - agonists (58) 58
original article (58) 58
drug administration schedule (57) 57
insulin - metabolism (56) 56
insulin secretion (55) 55
glucose metabolism (54) 54
hemoglobin (54) 54
glycated hemoglobin a - drug effects (52) 52
body mass index (51) 51
gip (51) 51
drug therapy, combination (50) 50
dose-response relationship, drug (48) 48
antidiabetic drug (47) 47
glucagon-like peptide 1 - metabolism (47) 47
glucagon-like peptide 1 - therapeutic use (46) 46
blood sugar (45) 45
incretin (44) 44
peptides - therapeutic use (43) 43
glp-1 receptor agonist (42) 42
hypoglycemia - chemically induced (42) 42
patients (42) 42
dipeptidyl-peptidase iv inhibitors - therapeutic use (41) 41
exendin-4 (41) 41
gastric-inhibitory polypeptide (41) 41
glp-1 receptor agonists (41) 41
glycaemic control (41) 41
insulin - blood (41) 41
rodents (41) 41
metabolism (40) 40
body weight - drug effects (39) 39
glp‐1 receptor agonist (39) 39
glucagon-like peptide 1 - blood (39) 39
hyperglycemia (39) 39
sitagliptin (39) 39
glucagon-like peptide 1 - administration & dosage (38) 38
insulin resistance (38) 38
peptides - administration & dosage (38) 38
peptides - pharmacology (38) 38
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Diabetes, Obesity and Metabolism, ISSN 1462-8902, 02/2018, Volume 20, pp. 47 - 58
The incretin therapies glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) and dipeptidyl peptidase‐IV (DPP‐IV) inhibitors are now well‐established as second... 
clinical trial | antidiabetic drug | cohort study | GLP‐1 analogue | DPP‐IV inhibitor | incretin therapy | GLP-1 analogue | DPP-IV inhibitor
Journal Article
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 01/2018, Volume 20, Issue 1, pp. 42 - 49
Journal Article
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 04/2016, Volume 18, Issue 4, pp. 317 - 332
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 10/2012, Volume 14, Issue 10, pp. 910 - 917
Aims To assess the efficacy and safety of once‐daily lixisenatide versus placebo in Asian patients with type 2 diabetes insufficiently controlled on basal... 
basal insulin | type 2 diabetes | Asian patients | GLP‐1 | lixisenatide | Type 2 diabetes | Basal insulin | GLP-1 | Lixisenatide | METFORMIN | GLYCEMIC CONTROL | EFFICACY | SAFETY | EXENATIDE | PEPTIDE-1 ANALOG LIRAGLUTIDE | HYPERGLYCEMIA | ENDOCRINOLOGY & METABOLISM | JAPANESE PATIENTS | WEIGHT | GLIBENCLAMIDE | Japan - epidemiology | Hypoglycemia - epidemiology | Receptors, Glucagon - antagonists & inhibitors | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Male | Peptides - administration & dosage | Diabetes Mellitus, Type 2 - epidemiology | Dose-Response Relationship, Drug | Hypoglycemic Agents - administration & dosage | Sulfonylurea Compounds - pharmacology | Philippines - epidemiology | Postprandial Period | Aged, 80 and over | Adult | Female | Hypoglycemia - blood | Sulfonylurea Compounds - administration & dosage | Drug Therapy, Combination | Republic of Korea - epidemiology | Body Mass Index | Insulin - pharmacology | Double-Blind Method | Drug Administration Schedule | Blood Glucose | Insulin - administration & dosage | Treatment Outcome | Hypoglycemia - drug therapy | Hypoglycemic Agents - pharmacology | Peptides - pharmacology | Asian Continental Ancestry Group | Diabetes Mellitus, Type 2 - blood | Glucagon-Like Peptide-1 Receptor | Taiwan - epidemiology | Adolescent | Aged | Diabetes Mellitus, Type 2 - drug therapy | Clinical trials | Blood sugar | Insulin | Diabetes therapy | Original
Journal Article
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 07/2013, Volume 15, Issue 7, pp. 642 - 649
ABSTRACT Aim Assess the pharmacodynamics of lixisenatide once daily (QD) versus liraglutide QD in type 2 diabetes insufficiently controlled on metformin.... 
metformin | receptor | type 2 diabetes | GLP‐1 | pharmacodynamics | Type 2 diabetes | Pharmacodynamics | GLP-1 | Metformin | Receptor | FASTING PLASMA-GLUCOSE | GLYCEMIC CONTROL | SAFETY | EXENATIDE | OPEN-LABEL | PEPTIDE-1 ANALOG | ENDOCRINOLOGY & METABOLISM | POSTPRANDIAL HYPERGLYCEMIA | DOUBLE-BLIND | GLP-1 RECEPTOR AGONIST | PLACEBO-CONTROLLED TRIAL | Glycated Hemoglobin A - analysis | Metformin - therapeutic use | C-Peptide - blood | Glucagon-Like Peptide 1 - administration & dosage | Humans | Middle Aged | Male | Glucagon - blood | Peptides - administration & dosage | Hypoglycemic Agents - administration & dosage | Injections, Subcutaneous | Adult | Female | Drug Resistance | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Drug Administration Schedule | Hyperinsulinism - prevention & control | Glucagon-Like Peptide 1 - analogs & derivatives | Diabetes Mellitus, Type 2 - blood | Incretins - adverse effects | Aged | Incretins - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Hypoglycemic Agents - adverse effects | Incretins - administration & dosage | Liraglutide | Peptides - adverse effects | Peptides - therapeutic use | Glucagon-Like Peptide 1 - therapeutic use | Care and treatment | Glucagon | Hypoglycemic agents | Glucose | Dextrose | Diabetes therapy | Original
Journal Article